{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-132621","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.076285+00:00","generated_at":"2026-06-16T03:48:48.788817+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biomea Fusion receives FDA clearance for IND of BMF-500 in relapsed/refractory acute leukemia","bullets":["FDA cleared IND for BMF-500, a novel covalent FLT3 inhibitor, to begin Phase I trial COVALENT-103 in adult patients with relapsed or refractory acute leukemia.","BMF-500 is the second investigational compound from Biomea's FUSION System to enter the clinic.","Preclinical data: BMF-500 showed ~20-fold greater potency than gilteritinib and >50-fold greater than reversible menin/MLL inhibitors in AML cell lines.","Combination of BMF-500 and BMF-219 showed greater than additive cell killing in acute leukemia cell lines and patient samples.","BMF-500 designed for high target selectivity with minimal off-target liabilities; potential for combinations with standard of care or BMF-219."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-132621","json":"https://secwatch.observer/filing/0001193125-23-132621.json","markdown":"https://secwatch.observer/filing/0001193125-23-132621.md","text":"https://secwatch.observer/filing/0001193125-23-132621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523132621/0001193125-23-132621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523132621/d851586d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:48:48.788817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}